Alternatively, and consistent with decreased waiting impulsivity in medicated TD and the pharmacological profile of aripiprazole, rodent studies have reported that waiting impulsivity can be reduced by administration of 5-HT1A/B and 5-HT2C agonists [53, 54] and 5-HT2A antagonists [55–57] as well as by D2 receptor agonists and antagonists [58, 59]. The gene discussed is HTR2C; the disease is thanatophoric dysplasia.